Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Lymphoma, Non-Hodgkin 15Neoplasm Metastasis 9Lymphoma, Large B-Cell, Diffuse 8Breast Neoplasms 8Lymphoma, Follicular 6Neoplasms 5Lymphoma 5Multiple Myeloma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Endometrial Neoplasms 4Prostatic Neoplasms 3Ovarian Neoplasms 3Lymphoma, Mantle-Cell 3Hodgkin Disease 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Lymphoma, T-Cell, Peripheral 2Hematologic Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 8Iodine-131 8Thyrotropin Alfa 5trametinib 4selpercatinib 4dabrafenib 4Vemurafenib 4lenvatinib 3cabozantinib 3Sunitinib 3Specimen Handling 3Sorafenib 3Radiofrequency Ablation 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3vandetanib 2entrectinib 2cobimetinib 2X-Rays 2Trastuzumab 2Thyroid (USP) 2Rosiglitazone 2Radiotherapy 2Nivolumab 2Interviews as Topic 2Gefitinib 2Everolimus 2Bortezomib 2AZD 6244 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thyroid Cancer, Papillary × copanlisib × Clear all
NCT04462471 2025-09-08

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
8 enrolled 8 charts
EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡